
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9144460/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. Clinical Pharmacology and Therapeutics, 2002, 71, 89-98.	4.7	164
2	CYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers. European Journal of Clinical Pharmacology, 2003, 59, 221-225.	1.9	95
3	Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions. European Journal of Clinical Pharmacology, 2004, 59, 869-873.	1.9	69
4	QTc Interval, CYP2D6 and CYP2C9 Genotypes and Risperidone Plasma Concentrations. Journal of Psychopharmacology, 2004, 18, 189-193.	4.0	69
5	Development of a PCR-based strategy for <i>CYP2D6</i> genotyping including gene multiplication of worldwide potential use. BioTechniques, 2005, 39, S571-S574.	1.8	68
6	Relation between CYP2D6 phenotype and genotype and personality in healthy volunteers. Pharmacogenomics, 2008, 9, 833-840.	1.3	66
7	Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity. Pharmacogenomics, 2009, 10, 17-28.	1.3	65
8	Lower frequency of CYP2C9*2 in Mexican-Americans compared to Spaniards. Pharmacogenomics Journal, 2004, 4, 403-406.	2.0	62
9	CYP2D6 genotype and debrisoquine hydroxylation phenotype in Cubans and Nicaraguans. Pharmacogenomics Journal, 2012, 12, 176-183.	2.0	62
10	QTc interval lengthening is related to CYP2D6 hydroxylation capacity and plasma concentration of thioridazine in patients. Journal of Psychopharmacology, 2002, 16, 361-364.	4.0	58
11	<i>CYP2D6</i> polymorphism: implications for antipsychotic drug response, schizophrenia and personality traits. Pharmacogenomics, 2007, 8, 1597-1608.	1.3	58
12	Determination of fluoxetine and norfluoxetine in human plasma by high-performance liquid chromatography with ultraviolet detection in psychiatric patients. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2003, 783, 25-31.	2.3	52
13	The Role of Cytochrome P450 Enzymes in the Metabolism of Risperidone and Its Clinical Relevance for Drug Interactions. Current Drug Targets, 2004, 5, 573-579.	2.1	52
14	Relation between <i>CYP2D6</i> genotype, personality, neurocognition and overall psychopathology in healthy volunteers. Pharmacogenomics, 2009, 10, 1111-1120.	1.3	49
15	Effect of Thioridazine Dosage on the Debrisoquine Hydroxylation Phenotype in Psychiatric Patients With Different CYP2D6 Genotypes. Therapeutic Drug Monitoring, 2001, 23, 616-620.	2.0	48
16	Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype. European Journal of Clinical Pharmacology, 2003, 59, 45-50.	1.9	46
17	CYP2C9 allele frequency differences between populations of Mexican-Mestizo, Mexican-Tepehuano, and Spaniards. Pharmacogenomics Journal, 2011, 11, 108-112.	2.0	46
18	CYP2D6 ultrarapid metabolism and early dropout from fluoxetine or amitriptyline monotherapy treatment in major depressive patients. Molecular Psychiatry, 2013, 18, 8-9.	7.9	46

#	Article	IF	CITATIONS
19	High risk of lifetime history of suicide attempts among CYP2D6 ultrarapid metabolizers with eating disorders. Molecular Psychiatry, 2011, 16, 691-692.	7.9	45
20	Determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography: application to the evaluation of CYP2D6 drug interactions. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2003, 783, 213-219.	2.3	40
21	Relationship between Risperidone and 9-hydroxy-risperidone Plasma Concentrations and CYP2D6 Enzyme Activity in Psychiatric Patients. Pharmacopsychiatry, 2002, 35, 231-234.	3.3	37
22	Low frequency of CYP2D6 poor metabolizers among schizophrenia patients. Pharmacogenomics Journal, 2007, 7, 408-410.	2.0	37
23	<i>CYP2D6</i> and the severity of suicide attempts. Pharmacogenomics, 2012, 13, 179-184.	1.3	37
24	Increased risk for major depression associated with the short allele of the serotonin transporter promoter region (5-HTTLPR-S) and the CYP2C9*3 allele. Fundamental and Clinical Pharmacology, 2007, 21, 451-453.	1.9	33
25	Neurological toxicity after phenytoin infusion in a pediatric patient with epilepsy: influence of CYP2C9, CYP2C19 and ABCB1 genetic polymorphisms. Pharmacogenomics Journal, 2013, 13, 359-361.	2.0	33
26	Influence of CYP2D6 Deletion, Multiplication, –1584C→G, 31G→A and 2988G→A Gene Polymorphisms on Dextromethorphan Metabolism among Mexican Tepehuanos and Mestizos. Pharmacology, 2010, 86, 30-36.	2.2	32
27	Interethnic Variability in <i>CYP2D6</i> , <i>CYP2C9</i> , and <i>CYP2C19</i> Genes and Predicted Drug Metabolism Phenotypes Among 6060 lbero- and Native Americans: RIBEF-CEIBA Consortium Report on Population Pharmacogenomics. OMICS A Journal of Integrative Biology, 2018, 22, 575-588.	2.0	32
28	Interethnic differences in the relevance of CYP2C9 genotype and environmental factors for diclofenac metabolism in Hispanics from Cuba and Spain. Pharmacogenomics Journal, 2014, 14, 229-234.	2.0	31
29	Relationship between CYP2C8 genotypes and diclofenac 5-hydroxylation in healthy Spanish volunteers. European Journal of Clinical Pharmacology, 2008, 64, 967-970.	1.9	30
30	Losartan hydroxylation phenotype in an Ecuadorian population: influence of <i>CYP2C9</i> genetic polymorphism, habits and gender. Pharmacogenomics, 2012, 13, 1711-1717.	1.3	28
31	CYP2C9 gene and susceptibility to major depressive disorder. Pharmacogenomics Journal, 2003, 3, 300-302.	2.0	27
32	CYP2D6 genotype and dextromethorphan hydroxylation phenotype in an Ecuadorian population. European Journal of Clinical Pharmacology, 2012, 68, 637-644.	1.9	27
33	Genomic Ancestry, <i><scp>CYP</scp>2D6</i> , <i><scp>CYP</scp>2C9</i> , and <i><scp>CYP</scp>2C19</i> Among Latin Americans. Clinical Pharmacology and Therapeutics, 2020, 107, 257-268.	4.7	27
34	CYP2D6 polymorphism in patients with eating disorders. Pharmacogenomics Journal, 2012, 12, 173-175.	2.0	25
35	CYP2D6 poor metabolizer status might be associated with better response to risperidone treatment. Pharmacogenetics and Genomics, 2013, 23, 627-630.	1.5	25
36	Clinical Implications of CYP2D6 Genetic Polymorphism During Treatment with Antipsychotic Drugs. Current Drug Targets, 2006, 7, 1671-1680.	2.1	24

#	Article	IF	CITATIONS
37	Association between T102C and A–1438G polymorphisms in the serotonin receptor 2A (5-HT2A) gene and schizophrenia: relevance for treatment with antipsychotic drugs. Clinical Chemistry and Laboratory Medicine, 2007, 45, 835-8.	2.3	23
38	<i>CYP2D6</i> -1584C>G promoter polymorphism and debrisoquine ultrarapid hydroxylation in healthy volunteers. Pharmacogenomics, 2013, 14, 1973-1977.	1.3	23
39	Reduced completed suicide rate in Hungary from 1990 to 2001: Relation to suicide methods. Journal of Affective Disorders, 2005, 88, 235-238.	4.1	22
40	Pharmacogenetics of the antiepileptic drugs phenytoin and lamotrigine. Drug Metabolism and Drug Interactions, 2011, 26, 5-12.	0.3	22
41	Influence of admixture components on CYP2C9*2 allele frequency in eight indigenous populations from Northwest Mexico. Pharmacogenomics Journal, 2013, 13, 567-572.	2.0	22
42	CYP2C9, CYP2C19, ABCB1 genetic polymorphisms and phenytoin plasma concentrations in Mexican-Mestizo patients with epilepsy. Pharmacogenomics Journal, 2016, 16, 286-292.	2.0	22
43	Analysis of diclofenac and its metabolites by high-performance liquid chromatography: relevance of CYP2C9 genotypes in diclofenac urinary metabolic ratios. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2003, 789, 437-442.	2.3	20
44	Association of common genetic variants with risperidone adverse events in a Spanish schizophrenic population. Pharmacogenomics Journal, 2013, 13, 197-204.	2.0	20
45	Lessons from Cuba for Global Precision Medicine: CYP2D6 Genotype Is Not a Robust Predictor of CYP2D6 Ultrarapid Metabolism. OMICS A Journal of Integrative Biology, 2017, 21, 17-26.	2.0	20
46	Prevalence of Potential Drug–Drug Interaction Risk among Chronic Kidney Disease Patients in a Spanish Hospital. Pharmaceutics, 2020, 12, 713.	4.5	19
47	QTc interval lengthening and debrisoquine metabolic ratio in psychiatric patients treated with oral haloperidol monotherapy. European Journal of Clinical Pharmacology, 2002, 58, 223-224.	1.9	18
48	Relationship between Haloperidol Plasma Concentration, Debrisoquine Metabolic Ratio,CYP2D6andCYP2C9Genotypes in Psychiatric Patients. Pharmacopsychiatry, 2004, 37, 69-73.	3.3	18
49	Interethnic differences in UGT1A4 genetic polymorphisms between Mexican Mestizo and Spanish populations. Molecular Biology Reports, 2013, 40, 3187-3192.	2.3	18
50	Antipsychotic drugs and QTc prolongation: the potential role ofCYP2D6genetic polymorphism. Expert Opinion on Drug Metabolism and Toxicology, 2007, 3, 9-19.	3.3	17
51	Relevance of <i>CYP2D6</i> -1584C>G polymorphism for thioridazine:mesoridazine plasma concentration ratio in psychiatric patients. Pharmacogenomics, 2009, 10, 1083-1089.	1.3	17
52	ATA homozigosity in the IL-10gene promoter is a risk factor for schizophrenia in Spanish females: a case control study. BMC Medical Genetics, 2011, 12, 81.	2.1	15
53	Relationship between the <i>CYP2C9</i> IVS8-109A>T polymorphism and high losartan hydroxylation in healthy Ecuadorian volunteers. Pharmacogenomics, 2014, 15, 1417-1421.	1.3	15
54	Determination of debrisoquine and 4-hydroxydebrisoquine by high-performance liquid chromatography: application to the evaluation of CYP2D6 genotype and debrisoquine metabolic ratio relationship. Clinical Chemistry and Laboratory Medicine, 2005, 43, 275-9.	2.3	13

#	Article	IF	CITATIONS
55	<i>CYP2D6</i> genetic polymorphisms in Southern Mexican Mayan Lacandones and Mestizos from Chiapas. Pharmacogenomics, 2014, 15, 1859-1865.	1.3	13
56	Interethnic relationships of <i>CYP2D6</i> variants in native and Mestizo populations sharing the same ecosystem. Pharmacogenomics, 2015, 16, 703-712.	1.3	13
57	Evaluating a newly developed pharmacogenetic array: screening in a Spanish population. Pharmacogenomics, 2010, 11, 1619-1625.	1.3	12
58	Use of pharmacogenetics in bioequivalence studies to reduce sample size: an example with mirtazapine and CYP2D6. Pharmacogenomics Journal, 2013, 13, 452-455.	2.0	12
59	MDR-1 genotypes and quetiapine pharmacokinetics in healthy volunteers. Drug Metabolism and Drug Interactions, 2013, 28, 163-166.	0.3	12
60	Relationships between CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 metabolic phenotypes and genotypes in a Nicaraguan Mestizo population. Pharmacogenomics Journal, 2021, 21, 140-151.	2.0	12
61	Evaluation of drug-metabolizing enzyme hydroxylation phenotypes in Hispanic populations: the CEIBA cocktail. Drug Metabolism and Drug Interactions, 2013, 28, 135-146.	0.3	11
62	Aripiprazole-Induced Parkinsonism and Its Association With Dopamine and Serotonin Receptor Polymorphisms. Journal of Clinical Psychopharmacology, 2008, 28, 352-353.	1.4	9
63	Liver enzyme abnormalities during antipsychotic treatment: a case report of risperidone-associated hepatotoxicity. Drug Metabolism and Drug Interactions, 2014, 29, 123-126.	0.3	9
64	Development of a HPLC method for the determination of losartan urinary metabolic ratio to be used for the determination of CYP2C9 hydroxylation phenotypes. Drug Metabolism and Drug Interactions, 2012, 27, 217-223.	0.3	8
65	Allele and genotype frequencies of genes relevant to anti-epileptic drug therapy in Mexican-Mestizo healthy volunteers. Pharmacogenomics, 2016, 17, 1913-1930.	1.3	8
66	High frequency of CYP2D6 ultrarapid metabolizer genotypes in an Ashkenazi Jewish population from Argentina. Pharmacogenomics Journal, 2017, 17, 378-381.	2.0	7
67	Development of a new genotyping assay for detection of the <i>BDNF</i> Val66Met polymorphism using melting-curve analysis. Pharmacogenomics, 2009, 10, 989-995.	1.3	6
68	CYP2D6Polymorphism and Mental and Personality Disorders in Suicide Attempters. Journal of Personality Disorders, 2014, 28, 873-883.	1.4	6
69	Influence of genetic variants and antiepileptic drug co-treatment on lamotrigine plasma concentration in Mexican Mestizo patients with epilepsy. Pharmacogenomics Journal, 2020, 20, 845-856.	2.0	6
70	<i>CYP2D6</i> Polymorphism and Mental and Personality Disorders in Suicide Attempters. Journal of Personality Disorders, 0, , 1-11.	1.4	4
71	Eating Disorder Symptoms and CYP2D6 Variation in Cuban Healthy Females: A Report from the Ibero-American Network of Pharmacogenetics. Current Pharmacogenomics and Personalized Medicine, 2012, 10, 288-292.	0.2	4
72	No effect of the CYP1A2*1F genotype on thioridazine, mesoridazine, sulforidazine plasma concentrations in psychiatric patients. European Journal of Clinical Pharmacology, 2007, 63, 527-528.	1.9	3

#	Article	IF	CITATIONS
73	Pharmacogenomics and Personality: Role of CYP2D6 and Implications for Psychopathology. Advances in Biological Psychiatry, 2010, , 30-45.	0.2	3
74	Reproducibility over time of the urinary diclofenac/4′-OH diclofenac ratio among differentCYP2C9 genotypes. European Journal of Drug Metabolism and Pharmacokinetics, 2003, 28, 213-215.	1.6	2
75	Research Highlights. Pharmacogenomics, 2011, 12, 311-313.	1.3	2
76	High-performance liquid chromatography method using ultraviolet detection for the quantification of aripiprazole and dehydroaripiprazole in psychiatric patients. Drug Metabolism and Drug Interactions, 2012, 27, 165-70.	0.3	2
77	CYP2C9 and clinical response to antidepressant drugs in Mexican-Americans. Clinical Pharmacology and Therapeutics, 2005, 77, P24-P24.	4.7	1
78	Research Highlights: Novel <i>CYP2C9</i> genetic polymorphisms and assessment of their impact on hydroxylation capacity. Pharmacogenomics, 2014, 15, 261-264.	1.3	1
79	Prevalence of foot disorders according to chronic kidney disease stage. Journal of Renal Care, 2021, 47, 17-26.	1.2	1
80	PP143—Impact of UGT1A4 genotype in the clinical response to lamotrigine in patients with epilepsy. Clinical Therapeutics, 2013, 35, e61.	2.5	0
81	PP148—Influence of CYP2C9 IVS8-109A>T Polymorphism on Losartan Oxidation in Healthy Ecuadorians. Clinical Therapeutics, 2013, 35, e64-e65.	2.5	0
82	PP139—Association of ABCB1, ABCC2, CYP2C9 and CYP2C19 polymorphism with phenytoin plasma concentrations. Clinical Therapeutics, 2013, 35, e59-e60.	2.5	0
83	PP157—CYP2C9 Allele Frequencies Among Three Costa Rican Ethnic Groups Compared With Hispanic Populations. Clinical Therapeutics, 2013, 35, e67-e68.	2.5	0
84	Research Highlights. Pharmacogenomics, 2013, 14, 603-606.	1.3	0
85	High prevalence of CYP2D6 ultrarapid metabolizers in a mestizo Colombian population in relation to Hispanic mestizo populations. Pharmacogenomics, 2020, 21, 1227-1236.	1.3	0
86	Incidence and factors associated with COVID-19 in 13 hemodialysis units. International Urology and Nephrology, 2022, 54, 715-716.	1.4	0
87	Relevance of <i>NR1I2</i> variants on carbamazepine therapy in Mexican Mestizos with epilepsy at a tertiary-care hospital. Pharmacogenomics, 2021, 22, 983-996.	1.3	0
88	Covid-19 in 40 dialysis facilities. A prospective multicenter cohort study in Spain. Portuguese Journal of Nephrology & Hypertension, 2021, 35, .	0.1	0
89	SAT0693â€Genetic polymorphisms and efficacy of metothrexate in rheumatoid arthritis. , 2018, , .		0
90	AB1296â€Genetic polimorphisms and methotrexate safety in rheumatoid arthritis. , 2018, , .		0

#	Article	IF	CITATIONS
91	Frequency of CYP2C9 Promoter Variable Number Tandem Repeat Polymorphism in a Spanish Population: Linkage Disequilibrium with CYP2C9*3 Allele. Journal of Personalized Medicine, 2022, 12, 782.	2.5	0